Literature DB >> 10957774

[Early detection of prostatic carcinoma in urologic practice with digital rectal examination and prostate-specific antigen. Early Detection Project Group].

H J Luboldt1, J Hüsing, J E Altwein, K H Bichler, D Czaja, P Fornara, K H Jöckel, K Schalkhäuser, L Weissbach, M Wirth, H Rübben.   

Abstract

For the early detection of prostate cancer, a patient should undergo digital rectal examination (DRE) and PSA investigation. Follow-up of increased PSA levels detects nearly 80% of cancers. Positive predictive value of suspicious DRE and PSA is about 50%. Whereas in the first evaluation of this case-finding trial about 70% of the patients had organ-confined cancers, nearly all of the detected cancers in the follow-up investigation were organ confined. The increased number of organ-confined cancers detected in early periodical examinations can lead to a reduction of mortality and morbidity from prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10957774     DOI: 10.1007/s001200050365

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  4 in total

1.  [Parameters to improve the specificity of the prostate-specific antigen. Early detection of prostate cancer].

Authors:  C Börgermann; S Kliner; A Swoboda; H-J Luboldt; H Rübben
Journal:  Urologe A       Date:  2011-09       Impact factor: 0.639

2.  [Treatment errors involving diagnosis using prostate specific antigen. Decisions of the commission of experts for medical mistakes of treatment of the state medical board of North Rhine].

Authors:  V Lent; F Baumbusch; G Weber
Journal:  Urologe A       Date:  2005-12       Impact factor: 0.639

Review 3.  [Differential therapy of prostate cancer].

Authors:  T Jäger; H Rübben; C Börgermann
Journal:  Internist (Berl)       Date:  2007-12       Impact factor: 0.743

4.  Colonoscopy effects on serum prostate specific antigen levels.

Authors:  C Barbatzas; A Dellis; I Grivas; N Trakas; A Ekonomou; A Kostakopoulos
Journal:  Int Urol Nephrol       Date:  2004       Impact factor: 2.370

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.